Eisai’s ER-820446 is a promising compound for the treatment of cerebral malaria. A selective inhibitor of Toll Like Receptor 9 (TLR9) signaling, ER-820446 has in some models significantly reducedmortality due to cerebral malaria. Pre-clinical development activities have been initiated in conjunction with researchers at the Oswaldo Cruz Foundation in Brazil and the University of Massachusetts in the USA.
The partnership frequently reviews the progress of the research and considers options for addressing any challenges.
|Location||North Africa and Middle East, Zimbabwe, Zambia, Uganda, Togo, Tanzania, Swaziland, Sudan, Southern Sudan, South Africa, Sierra Leone, Seychelles, Senegal, Sao Tome and Principe, Rwanda, Nigeria, Niger, Namibia, Mozambique, Mauritius, Mauritania, Mali, Malawi, Madagascar, Liberia, Lesotho, Kenya, Guinea-Bissau, Guinea, Ghana, Gambia, Gabon, Ethiopia, Eritrea, Equatorial Guinea, Cote d Ivoire, Congo, The Republic of, Congo, The Democratic Republic of, Comoros, Chad, Central African Republic, Cape Verde, Cameroon, Burundi, Burkina Faso, Brazil, Botswana, Benin, Angola, West Africa, Southern Africa, Eastern Africa, Central Africa|